

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

IN RE: OZEMPIC (SEMAGLUTIDE)	) MDL No. 22-MD-3038 (CFC)
PATENT LITIGATION	) ANDA CASE
	)
	)
	)
NOVO NORDISK INC. and	)
NOVO NORDISK A/S,	) ~~CONFIDENTIAL~~
	) ~~INFORMATION SUBJECT TO~~
	) ~~PROTECTIVE ORDER~~
Plaintiffs,	)
	)
v.	) C.A. No. 22-294 (CFC)
	) CONSOLIDATED
RIO BIOPHARMACEUTICALS INC.,	) ANDA CASE
et al.,	)
	)
Defendants.	)

**PLAINTIFFS' THIRD AMENDED DISCLOSURES TO DEFENDANTS
SUN PHARMACEUTICAL INDUSTRIES LTD. AND SUN
PHARMACEUTICAL INDUSTRIES, INC. PURSUANT TO RULE 26(a)(1)
OF THE FEDERAL RULES OF CIVIL PROCEDURE**

Pursuant to Fed. R. Civ. P. 26(a)(1), Plaintiffs Novo Nordisk Inc. and Novo Nordisk A/S (collectively, "Plaintiffs"), by their attorneys, hereby provide the following third amended disclosures to Defendants Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc. (collectively, "Sun").

These disclosures are based upon information reasonably and presently available to Plaintiffs, while discovery is ongoing. Plaintiffs reserve the right to supplement and/or amend these disclosures as necessary upon further investigation

Individual	Address	Subject
Vanessa Costain	Fenwick & West LLP	Certain information concerning sales and marketing of Ozempic®.
All persons knowledgeable	Sun Pharmaceutical Industries Ltd. (Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (East), Mumbai, Maharashtra, India 400063)	The Sun Product; research and development of the Sun Product; the Sun ANDA; Sun's decision to develop and file the Sun ANDA; subject matter disclosed and claimed in U.S. Patent Nos. 8,129,343; 8,920,383; 9,775,953; and 10,335,462.
All persons knowledgeable	Sun Pharmaceutical Industries, Inc. (2 Independence Way, Princeton, NJ 08540)	The Sun Product; research and development of the Sun Product; the Sun ANDA; Sun's decision to develop and file the Sun ANDA; subject matter disclosed and claimed in U.S. Patent Nos. 8,129,343; 8,920,383; 9,775,953; and 10,335,462.

CERTIFICATE OF SERVICE

I hereby certify that on July 28, 2023, I caused the foregoing to be electronically filed with the Clerk of the Court using CM/ECF, which will send notification of such filing to all registered participants.

I further certify that I caused copies of the foregoing document to be served on July 28, 2023, upon the following in the manner indicated:

Kelly E. Farnan, Esquire
Sara M. Metzler, Esquire
RICHARDS, LAYTON & FINGER, P.A.
One Rodney Square
920 North King Street
Wilmington, DE 19801
*Attorneys for Defendants Sun
Pharmaceutical Industries Ltd. and
Sun Pharmaceutical Industries, Inc.*

VIA ELECTRONIC MAIL

Brian Sodikoff, Esquire
KATTEN MUCHIN ROSENMAN LLP
525 West Monroe Street
Chicago, IL 60661
*Attorneys for Defendants Sun
Pharmaceutical Industries Ltd. and
Sun Pharmaceutical Industries, Inc.*

VIA ELECTRONIC MAIL

Christopher B. Ferenc, Esquire
KATTEN MUCHIN ROSENMAN LLP
2900 K Street NW, Suite 200
Washington, DC 20007
*Attorneys for Defendants Sun
Pharmaceutical Industries Ltd. and
Sun Pharmaceutical Industries, Inc.*

VIA ELECTRONIC MAIL

Christopher W. West, Esquire
KATTEN MUCHIN ROSENMAN LLP
550 South Tyron Street, Suite 2900
Charlotte, NC 28202
*Attorneys for Defendants Sun
Pharmaceutical Industries Ltd. and
Sun Pharmaceutical Industries, Inc.*

VIA ELECTRONIC MAIL

/s/ Travis J. Murray

Travis J. Murray (#6882)